807O Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)
Kohei Omatsu, J. Hamanishi, Noriyuki Katsumata, Shin Nishio, Kenjiro Sawada, Shintaro Takeuchi, Daisuke Aoki, Keiichi Fujiwara, Toru Sugiyama, Ikuo Konishi
Topics & Concepts
MedicineNivolumabGemcitabineClinical endpointInternal medicineHazard ratioOvarian cancerOncologyRandomized controlled trialGastroenterologyPhases of clinical researchChemotherapyUrologyCancerSurgeryConfidence intervalImmunotherapyOvarian cancer diagnosis and treatmentCancer Immunotherapy and BiomarkersCancer Research and Treatments